Protagenic Therapeutics granted new patent in Japan for modified stilbenoid
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 30 2025
0mins
Patent Grant Announcement: Protagenic Therapeutics received a patent (JP 7714571B) from the Japanese Patent Office on July 18, 2025, which is valid until March 31, 2041, covering a modified stilbenoid for treating epilepsy and seizures.
Company's Future Plans: The COO of Protagenic expressed optimism about the patent's significance for the company's pipeline and indicated intentions to seek similar patents in other regions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
